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performed to test the role of neoadjuvant chemotherapy. Some of 
these trials showed contradictory results (esp. Kelsen-RTOG(3) versus 
Allum/Clark-MRC(4)), but the overall 5-year survival advantage with 
neoadjuvant chemotherapy is probably <5%.(5) In most RCTs 
comparing neoadjuvant chemoradiotherapy followed by surgery versus 
surgery alone no significant benefit for the combined modality arm 
could be demonstrated. However, most of these (older) trials did not 
meet today’s standard of care and were generally underpowered. In 
the meta-analysis a survival benefit was suggested with the use of 
preoperative chemoradiotherapy.(6) 
Recently, we published the results of a multicenter Dutch RCT, 
comparing chemoradiotherapy (5 courses of weekly paclitaxel/ 
carboplatin and concurrent radiotherapy, 23x 1.8 Gy) followed by 
surgery versus surgery alone.(7) In general, toxicity was mild. In-
hospital mortality was comparable (4% in both groups) and no 
difference in postoperative morbidity was observed. The R0-radical 
resection rate was higher in the multimodality arm (92% vs. 69%). 
Median overall survival was superior in the multimodality arm (49% vs 
24%), while 5-year overall survival was 47% in the multimodality arm 
versus 34% in the surgery alone arm (p=0.003). Therefore, we now 
consider neoadjuvant chemoradiotherapy plus radical surgical 
resection as standard treatment for patients with potentially curable 
(cT1b-N1M0, cT2-4aNxM0) esophageal cancer. 
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In this short lecture, recent progress in radiation therapy (RT) for 
locally advanced esophageal cancer in Japan will be presented.  At 
present, concurrent chemotherapy (CT) of 5-FU/cisplatin combined 
with RT is a standard chemo-radiotherapy (CRT) regimen for locally 
advanced esophageal cancer.  Although full dose 5-FU/cisplatin is 
combined with RT in the USA, several Japanese investigators showed 
promising clinical results using low dose protracted infusion CT 
combined with full dose RT of 60-66 Gy for locally advanced 
esophageal squamous cell carcinomas.  Low dose protracted infusion 
of 5-FU or 5-FU plus cisplatin were proposed to reduce the acute 
toxicities due to concurrent CRT.  In addition, to obtain maximum 
radio-sensitization by CT, daily administration of low dose protracted 
CT combined with RT may be better than full dose short-term CT plus 
RT.  To test the above hypothesis, a randomized phase II study was 
conducted to compare the relative toxicity and efficacy of combining 
full dose short-term CT (arm A) or low dose protracted CT (arm B) 
with RT for esophageal cancer (KROSG0101/JROSG021) (1).  As a final 
analysis, low dose protracted infusion CT with RT is not superior to 
full dose short-term infusion CT with RT for esophageal cancer.  For 
both groups, late toxicities of grade 3 or more were noted 17-18% of 
the patients.  Most of the toxicities were cardiac or pleural toxicities, 
and patients with severe late toxicities often had coexistent 
hypothyroidism.         
To determine the clinical results of CRTfor esophageal cancer in 
Japan, a questionnaire-based survey for esophageal cancer treated by 
definitive RT between 1999 and 2003 was conducted (2).  Clinical 
results of definitive RT for patients were collected from 9 major 
institutions.  Only patients with good performance status (PS0-2) who 
received a total dose of 50 Gy or more were included.  Patients were 
classified into three groups; A) stage I-B) resectable stages II-III-C) 
unresectable stages III-IVA.  For group A, all patients treated by RT 
alone or chemo-radiotherapy (CRT) were included.  For groups B and 
C, only those treated by CRT were included.  The median total RT 
dose ranged from 60 Gy to 66 Gy.  The median and range of the 5-year 
overall survival rates were 56% (48-83%) for group A,29% (12-52%) for 
group B, and 19% (0-31%) for group C, respectively.  A significant 
disparity in survival rates wa snoted among the institutions for stage 
II-IVA tumors treated by CRT.  Interestingly, a significant correlation 
between the number of patients treated per year and the 5-year 
overall survival rate was noted for groups B and C (both p<0.05).  A 
similar volume-outcome relation was demonstrated between the 
number of esophagectomy operations performed per year and the 
operative mortality (3).  Thus, treatment of esophageal cancer should 
be done in limited number of large cancer center hospitals. 
To reduce the late toxicities, improvement in spatial dose distribution 
for esophageal cancer was obtained by conformal RT including 
intensity modulated RT (IMRT).  IMRT is an ideal boost technique for 
locally advanced cervical and upper thoracic esophageal cancers to 
exclude the spinal cord.  We are planning a phase II trial for cervical 
esophageal cancer using IMRT.   
References 
1) Nishimura Y, Hiraoka M, Koike R, et al.  Long-term follow-up of a 
randomized phase II study of cisplatin/5-FU concurrent chemo-
radiotherapy for esophageal cancer (KROSG0101/ JROSG021). Jpn J 
Clin Oncol 42:807-812, 2012 
2) Nishimura Y, Koike R, Ogawa K, et al.  Clinical practice and 
outcome of radiotherapy for esophageal cancer between 1999 and 
2003: The Japanese Radiation Oncology Study Group (JROSG) survey. 
IntJ Clin Oncol 17:48-54, 2012 
3) Fujita H, Ozawa S, Kuwano H, et al.  Esophagectomy for cancer: 
clinical concerns support centralization operations within the larger 
hospitals. Dis Esophagus 2010; 23:145-152. 
 
SP-0622   
Chemoradiation therapy for locally advanced esophageal cancer - 
European perspective 
W. Budach1 
1University Clinic Heinrich-Heine Univers. Dusseldorf, Radiation 
Oncology, Düsseldorf, Germany  
 
Radiotherapy in combination with concurrent cisplatin based 
chemotherapy of patients with locally advanced esophageal cancer 
results in 5 year overall survival between 10-30%. In meta-analysis of 
randomized trials comparing surgical treatment with or without 
neoadjuvant chemoradiation to chemoradiation, overall survival was 
identical (Hazard ratio 0.98) for both treatment strategies (1). 
Chemoradiation was associated with a significantly higher locoregional 
recurrence rate (HR:1.54) and a borderline significant lower distant 
metastases rate (HR 0.72; 95%CL 0.52 – 1.01). Treatment related 
mortality was higher with surgical treatment (8.9% vs. 1.3%). The vast 
majority of patients in these trials had squamous cell cancer. The lack 
of a survival benefit for surgery in spite of improved locoregional 
tumor control is mainly a consequence of the relatively high 
treatment related mortality. In randomized trials comparing surgery 
to neodjuvant chemoradiation followed by surgery (2), an increased 
treatment related mortality was reported for patients with squamous 
cell carcinomas, but not for patients with adenocarcinomas. Whether 
this observation is simply the consequence of the less complicated 
surgery of typically distally located adenocarcinomas or is also due to 
lifestyle associated differences in weight and cardiopulmonary 
function, is not well understood. The clinical consequence is that 
patients with locally advanced adenocarcinomas should be treated 
with neoadjuvant treatment followed by surgery, whereas patients 
with squamous cell cancer patients have two options, neoadjuvant 
chemoradiation followed by surgery or primary chemoradiation. Since 
treatment related mortality is higher in patients with impaired 
cardiopulmonary function or poor performance status, primary 
chemoradiation is the preferred treatment, if these conditions are 
present. Tumor location above the carina seems also to be associated 
with a higher risk of perioperative mortality favouring chemoradiation 
for the majority of these patients. Treatment decision based on early 
response to neoadjuvant chemoradiation has also been propagated. 
Patients with responding tumors have a much better clinical outcome 
regardless of whether treatment is completed with surgery of further 
chemoradiation (3), and chemoradiation as the less toxic treatment is 
propagated in case of response. Independent of these considerations, 
new treatment strategies are needed to improve clinical outcome. 
Chemoradiation with total doses between 50 to 65 Gy in combination 
with cisplatin based chemotherapy is standard at the time. The 
addition of taxanes and cetuximab is currently under investigation. 
Improved radiation technology like IMRT and IGRT are also under 
investigation and are expected to lower treatment related toxicity. 
